(Circulation. 1999;99:2283-2289.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the National Heart Institute, Inaba, Cairo, Egypt (A.E.-S.); Montreal General Hospital, Montreal, Quebec, Canada (T.H.); and the Clinical Cardiac Electrophysiology Laboratories of the Harvard Thorndike Electrophysiology Institute and Arrhythmia Services at Beth Israel Deaconess Medical Center, Boston, Mass (P.P., K.M., L.E., M.E.J.).
Correspondence to Mark E. Josephson, MD, Director of the Harvard Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave RW453, Boston, MA 02215. E-mail mjoseph2{at}bidmc.harvard.edu
| Abstract |
|---|
|
|
|---|
Methods and Results-Fifteen consecutive patients with
coronary artery disease and recurrent sustained VT underwent an
attempted RF ablation of 20 monomorphic VTs. Successful termination of
VT by a single RF lesion was predicted if all the following mapping
criteria were met: (1) an exact QRS match in the 12-lead ECG during
entrainment; (2) a return cycle length
10 ms of the VT cycle length;
(3) presystolic potentials (<70% of VT cycle length) with an
activation time to the QRS within 10 ms of the stimulus to QRS.
Inability to meet these 3 criteria was considered to predict failure of
VT termination by RF energy at that site. RF ablation was applied to 44
left ventricular sites in 20 VTs at which at least 1 of the
mapping criteria was met. VT was terminated with a single RF lesion in
19 of 19 sites meeting all criteria; RF failed to terminate VT at 24 of
25 sites at which all 3 criteria were not met
(P<0.0005).
Conclusions-To maximize success and minimize the number of RF lesions in patients with infarct-related VT, all the above 3 mapping criteria should be met before the application of RF energy.
Key Words: catheter ablation tachycardia mapping coronary artery disease
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Protocol
Electrophysiological procedures were
performed with the subjects in the fasting state after informed consent
was obtained. Quadripolar catheters (6F) were inserted
percutaneously through the femoral veins into the right
ventricular apex and right ventricular outflow
tract. A quadripolar 4-mm deflectable-tip mapping catheter with a
thermistor for monitoring temperature at the electrode tissue interface
was inserted into the left ventricle retrogradely through the femoral
artery. A bolus of 5000 U of heparin followed by an infusion of 1000 U
per hour was given before entry into the left ventricle. Programmed
ventricular stimulation was performed with a programmable
stimulator (Bloom Associates LTD) with the use of a current strength
twice the diastolic threshold. The intracardiac
electrograms and leads I, II, aVF, V1, and
V5 were displayed on an oscilloscope and
digitally recorded on optical disk by Cardio Laboratory system
(Prucka Engineering). Bipolar intracardiac electrograms recorded
from the distal and proximal electrode pair of the mapping catheter
were filtered at 30 to 500 Hz. Right ventricular
stimulation with up to 3 ventricular extrastimuli using up
to 3 basic drive train cycles at the right ventricular apex
and outflow tract was used to induce VT. Induced VTs were recorded
on a 12-lead ECG. Left ventricular mapping was performed as
previously described by Josephson et al.6 The mapping
catheter had a 4-mm ablation tip with 25-2mm spacing for proximal
electrodes. We used poles 1 to 3 (distal) and 2 to 4 (proximal) of the
ablation catheter for recording and poles 1 to 3 for
stimulation during VT with the lowest current that captured the VT at a
CL of 20 to 50 ms less than the VT CL. The pulse width was 2 ms in
duration. Catheter position was identified fluoroscopically in the
right and left oblique positions. Pacing was done at selected left
ventricular sites during VT, all of which exhibited
presystolic endocardial activation preceding the onset of the
QRS by
50 ms during VT, with the use of stimuli that captured the
ventricle with the least current as described above. Activation times
were taken from the onset of the electrogram. Twelve-lead ECGs during
pacing and VT were compared to evaluate if entrainment with fusion or
concealed entrainment was present. The return cycle (measured from
the stimulus to onset of the presystolic electrogram of the
first unpaced beat), local electrogram to QRS interval, stimulus to QRS
interval, and VT CL before pacing were measured on the distal bipolar
pair recording of the mapping catheter or with the use of the
proximal bipolar pair occasionally if artifacts were present in the
distal pole recording, preventing reliable measurement. The
proximal pair was always the same as that recorded during the
native tachycardia and was virtually indistinguishable from
the distal pair. We used right ventricular electrograms as
an additional reference to measure return cycles (right
ventricular return cycle should equal left
ventricular return cycle) and the relation between the left
ventricular site and the right ventricle (left
ventricular to right ventricular interval
during pacing should equal that during VT). The return cycle was
defined as the interval from the last paced beat to the first VT beat
(measured from the stimulus to onset of distal or proximal left
ventricular electrogram). Entrainment of VT with fusion was
defined as continuous resetting of VT with constant QRS fusion.
Entrainment of VT with concealed fusion was defined as continuous
resetting of VT by stimuli that did not alter the QRS configuration. An
exact 12-lead QRS match was defined as identical QRS morphology,
amplitude, slurring, and notching during pacing to the QRS of the VT
(Figure 1
). The following 3 criteria were
used to predict success or failure of RF in termination of VT: (1)
exact 12-lead QRS match during concealed entrainment; (2) return CL
within
10 ms of the VT CL with the use of both the distal and/or the
proximal electrodes on the ablation catheter and 1 or more right
ventricular reference electrograms; and (3)
presystolic potentials (70% VT CL) with local activation time
(electrogram) to QRS within
10 ms stimulus to QRS.
|
Stimulation was only performed at sites in which diastolic
electrograms were recorded in regions, based on VT ECG morphology,
suggested a possible site of origin. Before delivering a lesion, the
12-lead ECG during entrainment and intracardiac electrograms were
reviewed and a prediction of the response to the RF lesion was noted.
If the 3 criteria were fully met (Figure 2
), application of RF at this site was
predicted to be successful (Figure 3
). If
only 1 or 2 criteria were met, application of RF at this site was
predicted to be a failure. Once a target was selected, RF energy was
delivered as a continuous, unmodulated sine wave 500 kHz between the
distal electrode of the ablation catheter and a large skin electrode on
the posterior chest. Applications of RF energy were delivered during VT
at a power of 30 to 50 W with nontemperature-controlled catheters and
a target temperature of 65°C (range 60 to 70) when
temperature-controlled catheters were used. All lesions were delivered
for at least 1 minute unless a rise in impedance was noted. If the VT
terminated during RF application, the energy application was continued
for a total of 120 seconds. In the event of an impedance rise, the
ablation catheter was removed from the body and the distal electrode
was wiped clean of the coagulum before continuing with the procedure.
Programmed stimulation for induction of VT was repeated after
successful termination of VT by RF application either at the end of the
study or in a repeat study before hospital discharge 2 to 4 days after
the initial application in all patients except 2 who refused. Induced
nonclinical VT were not targeted if they were the only induced
tachycardias after the initial ablation. Another objective
of the study was to evaluate the clinical significance of these induced
tachycardias. Two of the nonclinical
tachycardias underwent attempted ablation (1 successful)
because they were in immediate proximity (on the basis of ECG
monitoring and activation mapping) to the clinical VT.
|
|
Clinical Follow-Up Data
The patients were followed at our arrhythmia clinic
periodically every 3 to 6 months for clinical recurrences. The
mean follow-up was 15 months (range 3 to 36 months).
Statistical Analysis
Values are expressed as mean±1 SD. Comparisons were
performed with the use of Student's t test and Fisher exact
test. A probability value of <0.05 was considered significant.
Positive predictive value was defined as true-positives/+
false-positives, and the negative predictive value was defined as
true-negatives/true-negatives+false-negatives.
| Results |
|---|
|
|
|---|
Successful termination of VT occurred in the first 10 seconds of the application of RF energy in 75% of VTs; 95% were terminated within 32 seconds. Nineteen of the 20 targeted VTs were terminated with an RF application at a single site. Eighteen of these were the clinically documented VT and 1 was a nonclinical (ie, induced but never before seen) VT. After RF ablation, all but 2 patients underwent ventricular stimulation. Only 1 clinical VT continued to remain inducible in a patient in whom the VT was reproducibly terminated at a site meeting all 3 criteria. The positive predictive value of these strict mapping criteria to predict VT termination with RF application at that site was 100%, whereas their negative predictive value was 96%. The sensitivity of these criteria was 94%; specificity was 100%.
Follow-Up
Patients were followed for a mean of 15±8.8 months. One patient
died from multiple cardiovascular accidents and
recurrent myocardial infarction 27 months after the ablation without
evidence of recurrent VT, 1 patient who had failure of VT ablation
(reproducible termination of VT by RF but persistently inducible) died
6 months later from progressive heart failure (no clinical VT
recurrence), and 1 patient died 3 years after VT ablation as
the result of progressive neurological disease (amyotrophic
lateral sclerosis). Two patients received an ICD after VT ablation
because the referring physician wanted therapy for inducible multiple
nonclinical VTs. There was no evidence of recurrence of ablated
VT. Four patients had recurrences of VT. In each instance it
was a stable VT inducible at
electrophysiological study but not targeted
for ablation. Electrocardiograms of the spontaneous VTs
in 2 patients without ICDs documented the QRS morphology. Both of these
patients underwent a second successful ablation. The 2 other VT
recurrences were in patients with ICDs. The electrograms and CL
of VTs in this ICD was compared with VT induced during ICD testing on
follow-up. This confirmed that the recurrence was of an induced
nonclinical VT and not the ablated VT. Antitachycardia
pacing was successful in both patients, therefore no further attempts
at ablation were made. All patients (5) receiving a stable dose of the
antiarrhythmic medication remained free of recurrence of
ablated VT. Three patients were discharged receiving no medication,
without evidence of recurrence of VT.
| Discussion |
|---|
|
|
|---|
10 ms of the VT CL with the use of both distal and/or proximal
electrodes on the ablation catheter and 1 or more right
ventricular reference electrograms; and (3)
presystolic potentials (70% VT CL) with local activation time
(electrogram) to QRS within
10 ms stimulus to QRS. We were able to
locate sites with all 3 suggested criteria in 19 of the 20 attempted
VTs (95%). The inability to find the appropriate target site in all
cases might be due to multiple reasons, including large amount of scar
tissue, intramyocardial or epicardial location of the VT isthmus, or
technical difficulty in catheter manipulation.3 18 In
addition, acceleration, termination, or changing of VT to a different
arrhythmia during attempts at entrainment limit the reality of
mapping all VT. In this study, the success rate for termination of VT by single RF application when the 3 criteria were met had a positive predictive value of 100% and negative predictive value of 96%. These results are not in contradiction of any previous studies but propose a more accurate method of selecting a successful site for ablation. The recent study by Bogun et al3 in 1997 found similar criteria helpful and, if combined, had a positive predictive value of 80% to 90%. Their study was a retrospective evaluation of sites of ablation, and multiple lesions may have been applied in an awe of interest. Thus no true predictable data about mapping accuracy could be gleaned from their report. The total number of VT ablated in this study was small; however, it was representative of the selected group of patients with VT caused by infarct scar. Of the 15 patients included in the present study, there were 2 patients who had ICD implantation before the ablation and 2 who had ICD implantation after the ablation because of induction of fast VT before discharge. There was no recurrence of the VT during the 15±8.8-month follow-up period.
The use of S-QRS equal to local electrogram to QRS is helpful in excluding sites which are bystanders. Stevenson et al2 in 1993 suggested from computer simulation analysis that an S-QRS interval >70% of the VT CL is suggestive of a site outside the isthmus. Of interest, Bogun et al did not find return CLs within 30 ms helpful either alone or in combination with the other criteria. Because our study looked prospectively at the use of 3 entrainment/mapping criteria together and required the return CL to be within 10 ms of the VT CL, we found it useful and necessary. Statistically, if during true concealed entrainment the S-QRS was equal to the local electrogram to the QRS and the S-QRS is <70% of the VT CL, there the return CL should equal the VT CL. We found that use of the right ventricular electrogram as a reference was helpful in confirming return cycle measurements, especially in cases in which noise in the recording of the distal electrode during pacing made the local measurements impossible.
Persistence of inducibility of VT after successful termination with single RF application despite further applications of RF energy at the same site is probably due to multiple reasons, for example, wide isthmus, epicardial location, or significant fibrosis and/or calcification,2 17 all of which suggest inadequate lesion size at the cause of failure.
The most interesting issue was the success of termination of VT at a site at which failure was predicted. This could occur if the site was not at the isthmus region but in the nearby vicinity with good conduction of temperature. It is also possible that the tip of the ablation catheter was at the isthmus but during pacing with a high current, a larger area was depolarized, resulting in fusion.
Early studies revealed a recurrence of ablated clinical VT or some of the induced nonclinical VT in up to 30%.13 19 We had no recurrences of ablated VTs or induced poorly tolerated nonclinical VT during follow-up. Our recurrence rate in this study might be affected by the short duration of follow-up or the total number of patients included. Although the natural history of recurrence of induced nonclinical VT was evaluated recently by Rothman and colleagues,5 patient selection may be important. In contrast to Rothman et al, none of our patients had prior ventricular fibrillation or were resuscitated from cardiac arrest. In addition, most of our patients had 1 to 2 spontaneous monomorphic VTs with a mean of 2.3 induced VTs, whereas in the study of Rothman et al,5 the mean induced VTs were 5.3±2.7. Tolerated or untolerated nonclinical VTs are not well defined in all prior published studies. The attempt to ablate multiple VTs, especially if they are not anatomically related or share a common isthmus, might be the cause of the difference in these results that is, higher recurrence rate. Also, none of our patients had prior cardiac arrest, and all were maintained on drugs that were used before ablation and made their VT slow and tolerable. Thus our patient population differed from that of Rothman et al in that we had no patients with cardiac arrest and all were maintained on the drugs present at the time of ablation. The goal of this study was to evaluate the success of termination of VT by RF application at a single site, not to establish the long-term recurrence of induced nonclinical VT.
Of note, 75% of ablated VT terminated within 10 seconds of the application of RF and 95% within 32 seconds. Although the total number of ablated VTs is small, successful termination of VT occurs within 30 seconds of RF application. We therefore, suggest discontinuation of RF energy application if there is no termination of VT by 30 seconds in order to decrease the likelihood of ablation of noninvolved myocardial tissue with impairment of left ventricular function.
This is the first study that prospectively tests the predictive accuracy of a specific set of entrainment/mapping criteria for guiding RF ablation of VT. Previous studies comparing the sensitivity and specificity of different entrainment criteria had lower predictive accuracy. Mid-diastolic potentials, which are unable to be dissociated from the tachycardia during pacing, have been used to guide ablation but they are uncommon and may still represent a bystander site attached to the isthmus.
Limitations
Potential limitations of this study are (1) activation times based
on bipolar recordings with a 4-mm electrode as the distal
electrode, (2) the possibility that RF energy might be delivered
distant to the recorded site, particularly using high current,
and/or produce damage beyond the recording/stimulation site,
and (3) measuring the return CL from the 2 to 4 pole if 1 to 3 pole had
interference (although we did validate the measurement by use of a
right ventricular electrogram as a reference), (4) bipolar
stimulation at relatively high milliampere used during entrainment
might result in capturing an area larger than the local area, (5) some
of the failed RF lesion might be due to inadequate heating or
inadequate lesion size rather than failure to identify the critical
zone of the tachycardia, (6) the number of patients
selected for this study is small and might not represent the
general population with sustained VT.2 5 13 17 19 This
study does not address the utility of ablation as primary therapy of
VT. A number of factors not addressed in this report are relevant to
answering this question, including: access to the left ventricle,
ability to induce VT, and the ability to completely map VTs.
Nevertheless, the use of these criteria results in successful
termination and potential "cure" of VT. Further studies are
necessary to allow a better understanding of how many lesions are
necessary to prevent recurrences or if a single larger lesion,
such a produced by a cool-tip catheter, would suffice if rigorous
mapping criteria were followed. While a prospective randomized trial of
RF attempts at sites meeting 1, 2, or all 3 criteria might provide a
more accurate assessment of true predictive value, the successful
termination of all tachycardias meeting these criteria and
only 1 of 25 not meeting them suggests these are valuable ablation
guides.
Conclusions
Although our data have limitations in terms of patient numbers,
the ability to successfully "cure" VT suggests that in appropriate
patients, RF ablation can be considered an option as a first line of
therapy for stable VT. Achievement of our strict entrainment/mapping
criteria is possible in the majority of clinical VT. To maximize
success and minimize the number of RF lesions, all 3
entrainment/mapping criteria should be met before the application of RF
energy. No patient had a cardiac arrest or rapid VT during follow-up
despite the frequent initiation of untolerated monomorphic and
polymorphic VT. The requirement of ablating all induced nonclinical
VT (tolerated and untolerated) remains to be established.
Received September 30, 1998; revision received January 22, 1999; accepted February 4, 1999.
| References |
|---|
|
|
|---|
10 ms of the VT cycle; and
(3) a stimulus to QRS
10 ms different than the diastolic
electrogram to QRS. RF was applied to 44 sites in 20 VT. VT was
terminated at 19 of 19 sites meeting all 3 criteria and failed in 24 of
25 sites failing to meet all criteria.This article has been cited by other articles:
![]() |
J. J. Blanc, J. Almendral, M. Brignole, M. Fatemi, K. Gjesdal, E. Gonzalez-Torrecilla, P. Kulakowski, G. Y.H. Lip, D. Shah, C. Wolpert, et al. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures Europace, May 1, 2008; 10(5): 513 - 527. [Full Text] [PDF] |
||||
![]() |
H. Doppalapudi, T. Yamada, H. T. McElderry, V. J. Plumb, A. E. Epstein, and G. N. Kay Ventricular Tachycardia Originating From the Posterior Papillary Muscle in the Left Ventricle: A Distinct Clinical Syndrome Circ Arrhythmia Electrophysiol, April 1, 2008; 1(1): 23 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Almendral and M. E. Josephson All Patients With Hemodynamically Tolerated Postinfarction Ventricular Tachycardia Do Not Require an Implantable Cardioverter-Defibrillator Circulation, September 4, 2007; 116(10): 1204 - 1212. [Full Text] [PDF] |
||||
![]() |
W. G. Stevenson and K. Soejima Catheter Ablation for Ventricular Tachycardia Circulation, May 29, 2007; 115(21): 2750 - 2760. [Full Text] [PDF] |
||||
![]() |
H. U. Klemm, R. Ventura, D. Steven, C. Johnsen, T. Rostock, B. Lutomsky, T. Risius, T. Meinertz, and S. Willems Catheter Ablation of Multiple Ventricular Tachycardias After Myocardial Infarction Guided by Combined Contact and Noncontact Mapping Circulation, May 29, 2007; 115(21): 2697 - 2704. [Abstract] [Full Text] [PDF] |
||||
![]() |
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF] |
||||
![]() |
V. Y. Reddy, P. Neuzil, M. Taborsky, and J. N. Ruskin Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-irrigated catheter J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2228 - 2236. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Strohmer and C. Hwang Ablation of postinfarction ventricular tachycardia guided by isolated diastolic potentials Europace, January 1, 2003; 5(4): 375 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zuliani, A. Cherubini, S. Volpato, E. Palmieri, P. Mecocci, P. De Rango, P. Cao, F. Costantini, A. Mezzetti, F. Mascoli, et al. Genetic Factors Associated With the Absence of Atherosclerosis in Octogenarians J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): M611 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Morton, P. Sanders, V. Deen, J. K. Vohra, and J. M. Kalman Sensitivity and specificity of concealed entrainment for the identification of a critical isthmus in the atrium: relationship to rate, anatomic location and antidromic penetration J. Am. Coll. Cardiol., March 6, 2002; 39(5): 896 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Josephson, D. J. Callans, and A. E. Buxton The Role of the Implantable Cardioverter-Defibrillator for Prevention of Sudden Cardiac Death Ann Intern Med, December 5, 2000; 133(11): 901 - 910. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |